Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innova...(ve greatlycontributed to the understandi...),Health

Date:10/22/2007

ve greatly contributed to the understanding of the process by which the virus infection leads to disease and have been shown to be an essential parameter in prognosis and management of HIV infected individuals. Decisions regarding initiation or changes in antiretroviral therapy are guided by monitoring plasma HIV-1 levels or viral load, CD4-T cell count and the patient's clinical condition. The goal of antiretroviral therapy is to reduce the virus in plasma to below detectable levels.

The RealTime HIV-1 test is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels. The assay is not intended to be used as a donor-screening test for HIV-1 or as a diagnostic test to confirm the presence of HIV-1 infection.

The RealTime HIV-1 test runs on the new Abbott m2000, an automated system that uses real-time polymerase chain reaction (PCR) to amplify, detect and measure minute levels of virus in blood samples as well as extremely high levels of these infectious agents. Real-time PCR enables the production of large quantities of DNA from very small samples in a short period of time, making it possible to detect extremely low levels of a virus's genetic material.

"The m2000 instrument in combination with the HIV-1 assay and Abbott-developed software gives clinical laboratories the ability to automatically and quickly measure very small levels of virus in patient samples, allowing labs to deliver highly accurate test results in a matter of hours," said Scott Safar, senior director, Systems Development and Support, Abbott Molecular.

About PathVysion

PathVysion is a test for breast cancer patients that provides physicians with genetic information to help them predict if a particular type of cancer treatment may be effective for an individual patient. PathVysi
'/>"/>

SOURCE Abbott Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
4. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
5. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
6. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
7. New Advances in Gastric Diagnostics: Smaller is Better
8. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
9. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
10. Non-Invasive Diagnostic Tests for Celiac Disease
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois